Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
S2Medical ABOSTO:S2M -3.70% 3-Year RORE % is -85.14 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 775 Medical Devices & Instruments companies, S2Medical AB ranks worse than 89.81% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
S2Medical AB's 3-Year RORE % for the quarter that ended in Dec. 2025 was -85.14%.
The industry rank for S2Medical AB's 3-Year RORE % or its related term are showing as below:
OSTO:S2M's 3-Year RORE % is ranked worse than 89.81% of 775
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs OSTO:S2M: -85.14
S2Medical AB (OSTO:S2M) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
S2Medical AB 3-Year RORE % Related Terms
S2Medical AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for S2Medical AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:S2M vs ISRG, BDX, MDLN: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, S2Medical AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
S2Medical AB 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, S2Medical AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where S2Medical AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
S2Medical AB (OSTO:S2M) has a 3-Year RORE % of -85.14 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on S2Medical AB and its competitors. According to the industry distribution chart, S2Medical AB ranks #696 out of 775 companies in the Medical Devices & Instruments industry, placing it in the top 89.8%.
Is S2Medical AB's 3-Year RORE % too high?
S2Medical AB's current 3-Year RORE % is -85.14. Based on the distribution chart, S2Medical AB ranks #696 out of 775 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does S2Medical AB's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, S2Medical AB ranks #696 out of 775 companies for 3-Year RORE %. This places S2Medical AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on S2Medical AB and its competitors. S2Medical AB's current 3-Year RORE % is -85.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S2Medical AB stock overvalued right now?
Based on GuruFocus' analysis, S2Medical AB (OSTO:S2M) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.01, compared to a current price of kr0.01 — trading 48% below its estimated fair value. The current 3-Year RORE % is -85.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For S2Medical AB (OSTO:S2M), the current 3-Year RORE % is -85.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
S2Medical AB is a research-intensive MedTech company from Sweden. The company develops products within the entire wound healing process from debridement and granulation to re-epithelialization. products for the initial phase of a wound's healing process until the end, when the wound is completely healed. S2Medical also has in its portfolio the product NoSmell for odor removal which is procured in several different Swedish healthcare regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:S2M has been successfully added to your 
